[go: up one dir, main page]

CO2017011536A2 - Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo - Google Patents

Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo

Info

Publication number
CO2017011536A2
CO2017011536A2 CONC2017/0011536A CO2017011536A CO2017011536A2 CO 2017011536 A2 CO2017011536 A2 CO 2017011536A2 CO 2017011536 A CO2017011536 A CO 2017011536A CO 2017011536 A2 CO2017011536 A2 CO 2017011536A2
Authority
CO
Colombia
Prior art keywords
antibody
combination
death
composition
compositions
Prior art date
Application number
CONC2017/0011536A
Other languages
English (en)
Inventor
Vikram SADINENI
Yong Quan
Wallace Kaserer
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55809254&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017011536(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO2017011536A2 publication Critical patent/CO2017011536A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que comprenden una combinación de un agente contra el cáncer que es un primer anticuerpo y un segundo anticuerpo. En algunas modalidades, el primer anticuerpo es un anticuerpo anti-muerte programada-1 (PD-1). En ciertas modalidades, la composición es una formulación de dosis fija. En ciertas modalidades, la composición se administra como una dosis uniforme. También un kit para tratar un sujeto afectado con una enfermedad, en donde el kit comprende una dosis de cualquier composición descrita en la presente e instrucciones para usar la composición en cualquiera de los métodos descritos para tratar una enfermedad.
CONC2017/0011536A 2015-04-17 2017-11-10 Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo CO2017011536A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562149325P 2015-04-17 2015-04-17
US201562265268P 2015-12-09 2015-12-09
US201562269000P 2015-12-17 2015-12-17
US201662303855P 2016-03-04 2016-03-04
PCT/US2016/027913 WO2016168716A1 (en) 2015-04-17 2016-04-15 Compositions comprising a combination of an anti-pd-1 antibody and another antibody

Publications (1)

Publication Number Publication Date
CO2017011536A2 true CO2017011536A2 (es) 2018-02-09

Family

ID=55809254

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0011536A CO2017011536A2 (es) 2015-04-17 2017-11-10 Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo

Country Status (32)

Country Link
US (4) US20160304607A1 (es)
EP (2) EP3283107B1 (es)
JP (3) JP6949718B2 (es)
KR (2) KR20250004095A (es)
CN (3) CN120381515A (es)
AU (2) AU2016249395B2 (es)
CA (1) CA2982839A1 (es)
CL (1) CL2017002636A1 (es)
CO (1) CO2017011536A2 (es)
CY (1) CY1123397T1 (es)
DK (1) DK3283107T3 (es)
EA (1) EA201792273A1 (es)
ES (1) ES2813580T3 (es)
HR (1) HRP20201334T1 (es)
HU (1) HUE050894T2 (es)
IL (3) IL289600B2 (es)
LT (1) LT3283107T (es)
MA (1) MA53243A (es)
MX (2) MX390954B (es)
MY (3) MY209024A (es)
NZ (1) NZ735820A (es)
PE (1) PE20180394A1 (es)
PH (1) PH12017501774A1 (es)
PL (1) PL3283107T3 (es)
PT (1) PT3283107T (es)
RS (1) RS60753B1 (es)
SG (2) SG11201708223QA (es)
SI (1) SI3283107T1 (es)
SM (1) SMT202000442T1 (es)
TN (1) TN2017000440A1 (es)
TW (3) TW202335681A (es)
WO (1) WO2016168716A1 (es)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
EA201591931A1 (ru) 2013-04-09 2016-05-31 Ликсте Байотекнолоджи, Инк. Композиции оксабициклогептанов и оксабициклогептенов
KR20160055269A (ko) 2013-09-20 2016-05-17 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
RS59134B1 (sr) 2014-05-13 2019-09-30 Medimmune Ltd Anti-b7-h1 i anti-ctla-4 antitela za tretman nesitnoćelijskog kancera pluća
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
KR102443258B1 (ko) 2014-08-12 2022-09-14 엘리게이터 바이오사이언스 에이비 항 cd40 항체에 의한 병용 치료제
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
ES2813580T3 (es) 2015-04-17 2021-03-24 Bristol Myers Squibb Co Composiciones que comprenden una combinación de ipilimumab y nivolumab
EP3288980B1 (en) 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
DK3322731T3 (da) * 2015-07-14 2021-03-08 Bristol Myers Squibb Co Fremgangsmåde til behandling af cancer ved hjælp af immun checkpoint-hæmmer; antistof der binder til programmed death-1-receptor (pd-1) eller programmed death ligand-1 (pd-l1)
SI3328419T1 (sl) 2015-07-30 2021-11-30 Macrogenics, Inc. PD-1-vezavne molekule in postopki uporabe le-teh
HRP20241381T1 (hr) 2015-08-11 2024-12-20 WuXi Biologics Ireland Limited Nova anti-pd-1 protutijela
EP3355920A4 (en) 2015-09-29 2019-05-15 Celgene Corporation PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods of use thereof
AU2016370376B2 (en) 2015-12-14 2023-12-14 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
BR112018012352A2 (pt) 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-lag3 e fragmentos de ligação ao antígeno
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
KR20220103806A (ko) 2016-05-18 2022-07-22 베링거 인겔하임 인터내셔날 게엠베하 암 치료용 항-pd1 및 항-lag3 항체
PL3458053T3 (pl) 2016-05-20 2022-04-25 Biohaven Therapeutics Ltd. Stosowanie riluzolu, proleków riluzolu lub analogów riluzolu z immunoterapiami w leczeniu nowotworów
SG10201911972QA (en) 2016-07-14 2020-02-27 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
AU2017329024A1 (en) 2016-09-19 2019-03-21 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
IL290857B2 (en) * 2016-12-08 2023-03-01 Lixte Biotechnology Inc Oxabicycloheptanes for immune response modulation
PL3565844T3 (pl) * 2017-01-09 2023-06-12 Tesaro Inc. Sposoby leczenia nowotworów złośliwych przeciwciałami anty-pd-1
TW202421659A (zh) 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
MX2019009772A (es) * 2017-02-21 2019-12-02 Regeneron Pharma Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
EP3600395A4 (en) * 2017-03-23 2021-05-05 The General Hospital Corporation BLOCKING OF CXCR4 / CXCR7 AND TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED DISEASE
KR20190141658A (ko) * 2017-03-29 2019-12-24 셀진 코포레이션 Pd-1 결합 단백질을 포함하는 제제 및 이의 제조 방법
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JP7408396B2 (ja) 2017-04-20 2024-01-05 アーデーセー セラピューティクス ソシエテ アノニム 併用療法
JP7402691B2 (ja) 2017-04-20 2023-12-21 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ２５抗体薬物複合体による併用療法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
MX2019013034A (es) * 2017-05-02 2020-02-05 Merck Sharp & Dohme Formulaciones estables de anticuerpos anti-ctla4 solos y en combinacion con anticuerpos contra el receptor de muerte programasa 1 (pd-1) y metodos para su uso.
TWI897843B (zh) * 2017-05-03 2025-09-21 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
CN110869392A (zh) 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
US11723975B2 (en) * 2017-05-30 2023-08-15 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
IL322104A (en) 2017-05-30 2025-09-01 Bristol Myers Squibb Co Treatment of lag-3 positive tumors
PL3638373T3 (pl) 2017-06-14 2025-04-14 Adc Therapeutics Sa Schematy dawkowania dla podawania ADC anty-CD19
US20190135905A1 (en) * 2017-06-16 2019-05-09 Bristol-Myers Squibb Company Compositions and methods for treating tauopathies
SG11201913137VA (en) 2017-07-11 2020-01-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
KR102798461B1 (ko) * 2017-08-18 2025-04-18 리제너론 파마슈티칼스 인코포레이티드 샘플 매트릭스에서 단백질 변이체를 분석하기 위한 이미지 모세관 등전 집속
CA3070774A1 (en) 2017-08-25 2019-02-28 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
CA3074565A1 (en) * 2017-09-05 2019-03-14 Merck Sharp & Dohme Corp. Compounds for reducing the viscosity of biological formulations
EP3679070A1 (en) 2017-09-07 2020-07-15 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
JP7256796B2 (ja) * 2017-10-13 2023-04-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
CA3077664A1 (en) * 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019108951A1 (en) * 2017-12-01 2019-06-06 Dana-Farber Cancer Institute, Inc. Compositions and methods for inhibiting dhhc-type palmitoyltransferases for cancer treatment
WO2019143607A1 (en) * 2018-01-16 2019-07-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EP3755720A1 (en) 2018-02-21 2020-12-30 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
AU2019228600A1 (en) 2018-03-02 2020-09-24 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof
JP7680208B2 (ja) * 2018-04-04 2025-05-20 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ２７抗体およびその使用
US20210147547A1 (en) * 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
EP3796942A1 (en) 2018-05-23 2021-03-31 ADC Therapeutics SA Molecular adjuvant
WO2019240872A1 (en) * 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
AU2019310636B2 (en) 2018-07-25 2025-06-26 Mayo Foundation For Medical Education And Research Gene signatures for predicting metastasis of melanoma and patient prognosis
SG11202102864XA (en) * 2018-10-19 2021-05-28 Bristol Myers Squibb Co Combination therapy for melanoma
AU2019375409A1 (en) * 2018-11-05 2021-05-27 Merck Sharp & Dohme Llc Dosing regimen of anti-TIGIT antibody for treatment of cancer
AU2019374748A1 (en) * 2018-11-05 2021-05-27 Merck Sharp & Dohme Llc Dosing regimen of anti-LAG3 antibody and combination therapy with anti-PD-1 antibody for treating cancer
CN120983617A (zh) * 2018-11-06 2025-11-21 健玛保 抗体配制剂
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
EP3876978A4 (en) 2018-11-07 2022-09-28 Merck Sharp & Dohme Corp. STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
CN119735694A (zh) 2018-11-13 2025-04-01 指南针制药有限责任公司 对抗检查点分子的多特异性结合构建体及其用途
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
CN114008071B (zh) 2018-12-27 2025-01-21 吉加根公司 抗ctla-4结合蛋白及其使用方法
SG11202107538VA (en) * 2019-01-16 2021-08-30 Compass Therapeutics Llc Formulations of antibodies that bind human cd137 and uses thereof
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
US11246847B2 (en) * 2019-07-18 2022-02-15 Delta-Fly Pharma, Inc. Anticancer drug effect enhancer
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
EP4074338A4 (en) * 2019-12-13 2024-03-06 Samsung Bioepis Co., Ltd. PHARMACEUTICAL PREPARATION OF STABLE ANTI-PD-1 ANTIBODY
US20230355757A1 (en) * 2019-12-20 2023-11-09 Formycon Ag Formulations of anti-pd1 antibodies
AR122359A1 (es) * 2020-01-08 2022-09-07 Bristol Myers Squibb Co Formulaciones de fgf-21 conjugado
KR20220131923A (ko) 2020-01-24 2022-09-29 리제너론 파마슈티칼스 인코포레이티드 안정한 항체 제형
BR112022014962A2 (pt) 2020-01-30 2022-09-20 Ona Therapeutics S L Terapia de combinação para tratamento de câncer e metástase de câncer
US20230118596A1 (en) * 2020-03-05 2023-04-20 Merck Sharp & Dohme Llc Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically accpetable salt thereof
EP4114445A1 (en) 2020-03-06 2023-01-11 Ona Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
JP7755863B2 (ja) * 2020-04-17 2025-10-17 シーフイダ ファーマシューティカル グループ （チーリン） カンパニー リミテッド Ｃｄ１３７と特異的に結合する製剤とその使用について
MY209953A (en) * 2020-06-19 2025-08-15 Sinocelltech Ltd Stable formulation for recombinant anti-pd-1 monoclonal antibody
WO2022006091A1 (en) * 2020-06-29 2022-01-06 Anovent Pharmaceutical (U.S.), Llc Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
AU2021299338A1 (en) * 2020-07-02 2023-02-23 Gigagen, Inc. Anti-CTLA-4 binding proteins and methods of use thereof
JP2023533963A (ja) * 2020-07-08 2023-08-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｃｔｌａ－４抗体を含む安定化製剤
WO2022073515A1 (zh) * 2020-10-11 2022-04-14 百奥泰生物制药股份有限公司 抗pd-1抗体在联合用药中的应用
EP4008345A1 (en) * 2020-12-03 2022-06-08 Hexal AG Novel formulations for antibodies
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
TW202308692A (zh) * 2021-04-27 2023-03-01 俄羅斯聯邦商拜奧卡德聯合股份公司 包含帕博利珠單抗（ｐｅｍｂｒｏｌｉｚｕｍａｂ）的藥學組成物及其用途
IL309310A (en) * 2021-06-18 2024-02-01 Genzyme Corp Antibody formulations against TGF-beta and their use
EP4355780A1 (en) * 2021-06-18 2024-04-24 Alligator Bioscience AB Novel combination therapies and uses thereof
AU2022303528A1 (en) * 2021-07-02 2024-01-25 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof
JP2024529502A (ja) 2021-07-30 2024-08-06 オーエヌエー セラピューティクス エセ．エレ． 抗ｃｄ３６抗体及び癌を治療するためのそれらの使用
US20240368284A1 (en) * 2021-09-03 2024-11-07 Dr. Reddy’S Laboratories Limited A method of improving stability of immune check point inhibitors
JP2024534206A (ja) * 2021-09-03 2024-09-18 ドクター レディズ ラボラトリーズ リミテッド 免疫チェックポイント阻害剤の医薬製剤
AU2023212994A1 (en) 2022-01-28 2024-08-08 Georgiamune Inc. Antibodies to programmed cell death protein 1 that are pd-1 agonists
JP2025518785A (ja) * 2022-06-02 2025-06-19 ブリストル－マイヤーズ スクイブ カンパニー 抗体組成物及びその使用方法
WO2024254395A2 (en) * 2023-06-09 2024-12-12 Orionis Biosciences, Inc. Clec9a-based chimeric protein formulations

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
IL129138A0 (en) 1996-10-11 2000-02-17 Bristol Myers Squibb Co Methods and compositions for immunomodulation
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
KR20020012292A (ko) 1999-06-25 2002-02-15 제넨테크, 인크. 항-ＥｒｂＢ 항체-메이탄시노이드 결합체를 사용한 치료방법
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7034121B2 (en) 2000-01-27 2006-04-25 Genetics Institue, Llc Antibodies against CTLA4
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
CA2492143A1 (en) * 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
PL375144A1 (en) 2002-07-30 2005-11-28 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
KR20060079180A (ko) 2003-07-02 2006-07-05 노보 노르디스크 에이/에스 Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
US7803376B2 (en) 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2006003179A2 (en) 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
EP1836225B1 (en) 2005-01-06 2011-11-02 Novo Nordisk A/S Kir-binding agents and methods of use thereof
WO2006096490A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc ANTI-MAdCAM ANTIBODY COMPOSITIONS
CN101325968B (zh) * 2005-03-08 2014-04-23 辉瑞产品公司 抗ctla-4抗体组合物
CA2602777C (en) 2005-03-25 2018-12-11 Tolerrx, Inc. Gitr binding molecules and uses therefor
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US9447185B2 (en) 2005-10-14 2016-09-20 Innate Pharma, S.A. Compositions and methods for treating proliferative disorders
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
ES2579768T3 (es) 2007-01-11 2016-08-16 Novo Nordisk A/S Anticuerpos anti-KIR, formulaciones y usos de los mismos
JP2008278814A (ja) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
DK2175884T3 (en) 2007-07-12 2016-09-26 Gitr Inc Combination USING GITR BINDING MOLECULES
US8268970B2 (en) 2007-10-01 2012-09-18 Bristol-Myers Squibb Company Human antibodies that bind mesothelin, and uses thereof
WO2009073533A2 (en) 2007-11-30 2009-06-11 Medarex, Inc. Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CN102105787A (zh) * 2008-05-29 2011-06-22 百时美施贵宝公司 用于预测患者对共刺激通道调节的应答的方法
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
EP2350649A4 (en) 2008-11-28 2012-11-14 Abbott Lab STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME
EP2367553B1 (en) 2008-12-05 2017-05-03 Novo Nordisk A/S Combination therapy to enhance nk cell mediated cytotoxicity
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
SG178991A1 (en) 2009-09-03 2012-04-27 Schering Corp Anti-gitr antibodies
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
NZ602892A (en) 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
BR112013012138B1 (pt) 2010-11-22 2022-02-22 Innate Pharma Sa Uso de um composto que inibe um receptor inibidor de célula natural killer (nkcir)
WO2012122444A1 (en) 2011-03-10 2012-09-13 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
AU2012236479B2 (en) * 2011-03-31 2016-10-20 Merck Sharp & Dohme Llc Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
ES2669310T3 (es) 2011-04-20 2018-05-24 Medimmune, Llc Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
EA036545B1 (ru) 2011-05-25 2020-11-20 Иннейт Фарма, С.А. Анти-kir антитела для лечения воспалительных заболеваний
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
KR102024957B1 (ko) 2011-11-09 2019-09-24 브리스톨-마이어스 스큅 컴퍼니 항-cxcr4 항체를 이용한 혈액 악성종양의 치료
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
KR101566538B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ17 세포 전환용 에피토프 및 이의 용도
IN2014KN00920A (es) * 2012-06-21 2015-10-09 Compugen Ltd
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US20150290316A1 (en) * 2012-10-02 2015-10-15 Bristol-Myers Squibb Company Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
KR20140119396A (ko) * 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
KR101809151B1 (ko) * 2013-07-18 2017-12-15 (주)앗코스텍 키레놀 또는 희첨 추출물을 포함하는 골다공증 예방, 개선 또는 치료용 조성물
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
PT3702373T (pt) 2013-09-13 2022-09-27 Beigene Switzerland Gmbh Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
KR20160055269A (ko) 2013-09-20 2016-05-17 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
CA2951234C (en) 2014-06-06 2022-05-31 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
ES2813580T3 (es) * 2015-04-17 2021-03-24 Bristol Myers Squibb Co Composiciones que comprenden una combinación de ipilimumab y nivolumab
KR20170138555A (ko) * 2015-04-28 2017-12-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 항-ctla-4 항체를 사용한 pd-l1-음성 흑색종의 치료
WO2016196389A1 (en) * 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
TWI821748B (zh) * 2015-11-18 2023-11-11 美商必治妥施貴寶公司 使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌
CN109348714A (zh) * 2016-05-04 2019-02-15 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
JP2019516682A (ja) * 2016-05-04 2019-06-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
CN109414420A (zh) * 2016-05-04 2019-03-01 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
WO2017192813A1 (en) * 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
KR20240134249A (ko) * 2016-06-03 2024-09-06 브리스톨-마이어스 스큅 컴퍼니 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
JP2019517498A (ja) * 2016-06-03 2019-06-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体
WO2018039518A1 (en) * 2016-08-26 2018-03-01 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3503891A1 (en) * 2016-08-26 2019-07-03 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11649212B2 (en) * 2017-10-09 2023-05-16 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11203592B2 (en) * 2017-10-09 2021-12-21 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019136112A1 (en) * 2018-01-05 2019-07-11 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023356A1 (en) * 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11554120B2 (en) * 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
US10959986B2 (en) * 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) * 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use

Also Published As

Publication number Publication date
TWI733664B (zh) 2021-07-21
KR20170138477A (ko) 2017-12-15
MX2022003572A (es) 2022-04-25
BR112017021688A2 (pt) 2018-08-14
IL289600A (en) 2022-03-01
CN113577264B (zh) 2025-05-27
JP2024009946A (ja) 2024-01-23
TW202206101A (zh) 2022-02-16
CN107743401B (zh) 2021-08-24
RS60753B1 (sr) 2020-10-30
MY209024A (en) 2025-06-17
EP3283107B1 (en) 2020-05-27
US20170143827A1 (en) 2017-05-25
HUE050894T2 (hu) 2021-01-28
IL289600B1 (en) 2025-05-01
IL289600B2 (en) 2025-09-01
NZ735820A (en) 2025-02-28
MY198237A (en) 2023-08-16
AU2016249395A1 (en) 2017-10-19
JP2018513159A (ja) 2018-05-24
TWI787880B (zh) 2022-12-21
AU2022204037A1 (en) 2022-06-30
WO2016168716A1 (en) 2016-10-20
US20200197518A1 (en) 2020-06-25
US20240091354A1 (en) 2024-03-21
IL320342A (en) 2025-06-01
SG11201708223QA (en) 2017-11-29
IL255072A0 (en) 2017-12-31
LT3283107T (lt) 2020-09-10
EA201792273A1 (ru) 2018-04-30
MX390954B (es) 2025-03-21
PH12017501774A1 (en) 2018-03-19
HRP20201334T1 (hr) 2020-11-27
TW201709930A (zh) 2017-03-16
KR20250004095A (ko) 2025-01-07
CY1123397T1 (el) 2021-12-31
SG10201912035YA (en) 2020-02-27
CL2017002636A1 (es) 2018-06-01
EP3283107A1 (en) 2018-02-21
PT3283107T (pt) 2020-08-31
US10512689B2 (en) 2019-12-24
KR102740444B1 (ko) 2024-12-10
MY188749A (en) 2021-12-28
CN113577264A (zh) 2021-11-02
DK3283107T3 (da) 2020-08-31
PE20180394A1 (es) 2018-02-28
MX2017013270A (es) 2018-01-25
AU2016249395B2 (en) 2022-04-07
IL255072B (en) 2022-02-01
MA53243A (fr) 2021-06-23
CN107743401A (zh) 2018-02-27
HK1247099A1 (en) 2018-09-21
ES2813580T3 (es) 2021-03-24
CN120381515A (zh) 2025-07-29
JP6949718B2 (ja) 2021-10-13
PL3283107T3 (pl) 2020-12-14
EP3738610A1 (en) 2020-11-18
US20160304607A1 (en) 2016-10-20
TW202335681A (zh) 2023-09-16
CA2982839A1 (en) 2016-10-20
SMT202000442T1 (it) 2020-09-10
US11612654B2 (en) 2023-03-28
TN2017000440A1 (en) 2019-04-12
SI3283107T1 (sl) 2020-10-30
JP2022008479A (ja) 2022-01-13

Similar Documents

Publication Publication Date Title
CO2017011536A2 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
MX2019001481A (es) Derivado de oxopicolinamida, metodo de preparacion y uso farmaceutico del mismo.
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
CL2017002792A1 (es) Derivados de ciclohexano sustituido con amido
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
BR112017011536A2 (pt) terapias de combinação
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
MX2018013240A (es) Composiciones antiirritantes sinergisticas de taurina y aloe.
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000007A (es) Pirazolpiridinas sustituidas
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
ECSP20023626A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
MX2018016332A (es) Quimioterapias de combinacion.
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
MX2017009482A (es) Formulación farmacéutica.
BR112016017897A8 (pt) uso de composto de carboxamida heterocíclica de diamino no tratamento de câncer relacionado ao axl, composição farmacêutica e combinação
MX2018015916A (es) Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
MX2019000717A (es) Composiciones que comprenden una matriz de polisacarido para la liberacion controlada de ingredientes activos.
AR133719A2 (es) Composiciones que comprenden una combinación de un anticuerpo anti-pd-1 y otro anticuerpo
AR117405A1 (es) Uso de conjugados anticuerpo-fármaco que comprenden agentes que alteran la tubulina para tratar tumores sólidos